/quality/85/?url=http://media.beam.usnews.com/3c/802000280aa0cef40e7935498fc35d/tag:reuters.com,2020:newsml_LYNXMPEG9D14N:22020-10-14T133159Z_2_LYNXMPEG9D14N_RTROPTP_3_HEALTH-CORONAVIRUS-AIRLINES-AIRPORTS.JPG">

SYDNEY, Oct 14 (Reuters) – Only 28% of participants in the air cargo industry feel they are well prepared to distribute a COVID-19 vaccine once available, according to a survey released on Wednesday, as the industry begins to gear up for a major logistical challenge.

Ground handlers and airports feel less prepared than freight forwarders and airlines, according to the survey conducted by The International Air Cargo Association (TIACA) and Pharma.Aero which found 36% of participants planned to invest in additional physical or digital infrastructure.

TIACA Vice Chairman Sanjeev Gadhia, who heads Nairobi-based air cargo operator Astral Aviation, said the global distribution of the COVID-19 vaccine would be the toughest logistical challenge ever faced, with an estimated 10 billion doses requiring distribution in 2021 and 2022.

More than 40 vaccine candidates are already undergoing clinical trials, according to the World Health Organization.

“We know that as from November the first

Read More

By Suzanne Barlyn and Swati Pandey

NEW YORK/SYDNEY, Oct 14 (Reuters)Asian equities slipped on Wednesday as halted COVID-19 vaccine trials and an impasse in U.S. fiscal aid package talks soured risk appetite, while the greenback held on to gains as demand firmed for safe-harbour assets.

Johnson & Johnson JNJ.N on Tuesday said it was pausing a COVID-19 vaccine trial due to a study participant’s unexplained illness.

Eli Lilly and Co LLY.N later said it too had paused the clinical trial of its COVID-19 antibody treatment due to a safety concern, leading the U.S. equity market to deepen losses.

J&J shares lost 2.3%, while Eli Lilly closed down nearly 3%.

“That just spoke to the fact that a vaccine could take longer to be delivered than what the market’s expectations are calibrated towards,” said CommSec market analyst Tom Piotrowski in Sydney.

MSCI’s broadest index of Asia-Pacific shares outside

Read More

The Tuesday Market Minute

  • Global stocks mixed as concerns for a pause in Johnson & Johnson’s coronavirus vaccine trial is partly offset by solid China trade data.
  • Johnson & Johnson becomes the second “Operation Warp Speed’ trial to pause following the unexplained illness of one of its participants, raising questions about the efficacy of the andenovirus technique.
  • China posts a 13.2% surge in September imports, narrowing its trade surplus with the United States to $30.75 billion.
  • European stocks slide as lockdowns accelerate around the region and a key reading of investor sentiment from Germany disappoints.
  • Oil prices bump higher following the stronger-than-expected China trade data and output returns in Norway and the U.S. Gulf.
  • U.S. equity futures suggest a mixed open on Wall Street ahead of the unofficial start to the third quarter earnings season with updates expected from Johnson & Johnson, JPMorgan, Citigroup and Delta Airlines.

U.S. equity futures

Read More

Topline

Third-quarter earnings season officially kicks off this week with big banks, airlines and consumer-staple firms set to report on Tuesday, and though Wall Street’s eyeing improvements over the previous quarter, a sustained economic recovery is still ultimately contingent on widespread vaccination.

Key Facts

Big banks and airlines–two of the coronavirus pandemic’s worst-hit industries–kick off earnings season on Tuesday, with JPMorgan Chase, Citigroup and Delta Air Lines all set to report before the opening bell.

Expect weak and uneven sales growth, and a collapse in profit margins, to characterize third-quarter results, Goldman Sachs said in a weekend note to clients, adding that it still expects election results will have more

Read More

Researchers in the United Kingdom have begun testing the impact of the BCG (Bacillus Calmette-Guerin) vaccine in preventing Covid-19 infections among healthcare workers.

The BCG vaccine developed in 1921 is primarily meant to prevent tuberculosis infections in patients. As part of an international trial to study the effects of the vaccine in preventing Covid-19 infections, scientists will test the vaccine on healthcare workings.

New vaccine Trials

The UK trial is being conducted by the UK arm of the BRACE trial, Exeter Medical School in collaboration with the Murdoch Children’s Research Institute (MCRI) in Melbourne, Australia.

“BCG has a number of what is called off-target effects and there is evidence in the scientific literature of its potential effects against a number of viral infections including against corona type of viruses such as influenza or respiratory sensitive virus (RSV),” said Professor John Campbell, Professor of General Practice and Primary Care who is

Read More

US President Donald Trump accused the Food and Drug Administration (FDA) of carrying out a political hit job against him by releasing new standards that could delay authorisation of a coronavirus vaccine until after the November election.

New FDA rules make it more difficult for them to speed up vaccines for approval before Election Day. “Just another political hit job!” the President wrote in a tweet that tagged his hand-picked FDA commissioner, Stephen Hahn.

Trump, who is battling a coronavirus infection himself, commented hours after the FDA issued strict new requirements for Covid-19 vaccine applications, including a review by a panel of experts and two months of safety data. The guidelines are intended to reassure the American public any vaccine is safe and effective, amid accusations that the Trump administrations response to the virus has been tainted by politics.

The FDA declined to comment.

Trump, whose re-election hinges on how

Read More

Text size

An engineer works in the general laboratory during a media tour of a new factory built to produce a COVID-19 coronavirus vaccine


WANG ZHAO/AFP/Getty Images

A briefing document published today by the U.S. Food and Drug Administration makes it clear that President Trump won’t be able to push through a Covid-19 vaccine before November’s election.

The FDA posted the 38-page briefing on its website, ahead of an Oct. 22 meeting of the agency’s outside scientific advisors on development and authorization of Covid vaccines. Inside, the agency reports that it has advised vaccine developers not to apply for an emergency use authorization until they’ve followed-up on clinical trial participants for an average of two months after the last shot.

A two month follow-up would make it late November for the vaccine being tested by

Pfizer

(ticker: PFE) and

BioNTech

(BNTX), writes Raymond James analyst Steven Seedhouse in a Tuesday

Read More


  • Goldman’s David Kostin told CNBC on Tuesday that markets are expecting a blue wave election victory, citing polling and betting market data. 
  • The chief US equity strategist said that consequential moves in the market may not be that dramatic because a large fiscal stimulus may offset higher taxes proposed by a Democratic government. 
  • He added that ultimately a vaccine for the coronavirus is more important for the future of the US economy than who wins the election. 

Goldman Sachs’ David Kostin told CNBC on Tuesday that markets are pricing in a blue wave victory, and consequential moves after the election may not be dramatic. 

The chief US equity strategist said investors are looking at polling and betting markets that have recently demonstrated a consensus expectation of a blue wave. He also said that the recent back-up in interest rates could be because investors are expecting a large

Read More

The developmental strategy for a vaccine for seasonal influenza will pave the way for the upcoming vaccines for the coronavirus, according to a the study published in the Journal of the American College of Cardiology.

The researchers explored whether existing flu prevention strategies could offer primary and secondary prevention strategies for coronavirus, especially for Covid-19 patients with cardiovascular issues.

According to World Health Organisation (WHO) estimates, influenza kills as many as 6.5 lakh people every year globally.

Also read: Influenza vaccine doesn’t increase Covid-19 health risks: Study

The multilateral organisation sees influenza as one of the top 10 leading causes of death among people of all ages, especially those with one or more comorbidities like cardiovascular disease.

Research has shown that viral respiratory infections such as seasonal influenza and Covid-19 are risk factors for cardiovascular disease.

Study author Jacob A Udell from the University of Toronto in Canada, said in

Read More

This analysis is by Bloomberg Intelligence senior analysts Eric Balchunas and Athanasios Psarofagis. It appeared first on the Bloomberg Terminal.

The hunt for a COVID-19 vaccine is fueling early gains for a new theme exchange-traded fund, GERM, which has higher allocations to companies such as Inovio, Novavax and Moderna than any other ETF. A similar-sounding ETF isn’t getting the same boost, highlighting the importance of due diligence in the increasingly popular thematic category.

GERM’s all-in design pays off immediately

The ETFMG Treatments Testing and Advancements ETF (GERM) was up 13% in its first two weeks, offering a reminder of how crucial index design is for theme ETFs. GERM is highly focused, going all-in on biotech names that aim to treat and prevent viruses, including some companies pursuing a COVID-19 vaccine. Inovio and Novavax are responsible for about half of the ETF’s gain. No ETF has a bigger weighting to either

Read More